Innate Pharma announces today a capital increase of a maximum of 24.3 million euros reserved to categories of investors

  • The “Fonds Stratégique d’Investissement” (French sovereign fund) invested 11 million euros
  • Novo Nordisk A/S and Alta Partners, two historical shareholders of the Company, also participated in the transaction
PR in english 42.89 KB
CP en français 42.71 KB